Abstract 2281
Background
TM is a useful tool that improves access to medical care for rural residents. However, factors that correlate with a positive TM experience are not well known. The study aims to determine TM experience in cancer patients and physicians, and to explore clinical and socio-economic factors (CSF) that are associated with a positive TM experience in patients.
Methods
In this cross-sectional study cancer patients on active treatment and physicians in the province of Saskatchewan, Canada completed a paper-based comprised of 32 items or an electronic survey of 18 items, respectively. Six point likert score was used. Logistic regression analysis was done to assess correlation between self-reported CSF and a positive TM experience. We present here preliminary results.
Results
Overall 25 physicians and 165 patients responded to the survey over a period of three months. Among physicians 69% were in practice for ≥10 yrs with M:F of 1.7:1. 94% were confident in their TM assessment, 58% felt that TM improve clinical efficiency, and 74% felt that doctor-patient rapport was unimpaired with TM. Of 165 patients with median age of 67 years (IQR 59-75) and M:F of 1.06:1, 60% were ≥65 yrs, 70% were married, and 82% had a dependent family member. 94% were born in Canada, 77% were Caucasian, 29% were working and 35% had annual income of < 40K. 67% had solid tumor, 46% reported having a curable cancer, 31% had surgery, 27% had radiation, and 62% had chemotherapy. 61% used TM first time. 90% felt that their needs were met, 91% felt that TM improved their quality of care, and 91% had a good experience. Overall, 83% patients vs. 45% physicians preferred TM to in-person clinic visit (P = 0.005). Only univariate analysis only age ≥65 was strongly associated with a positive TM experience, odd ratio 4.1 (1.2-13.8), p = 0.02. No other CSF including marital status, income, working status, dependent family member, and cancer type were significantly correlated with a positive TM experience.
Conclusions
This study supports a higher rate of positive TM experience in cancer patients and physicians. However, high preference of TM was noted among patient compared with physicians. Among various variables examined only older age was associated with a positive TM experience.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shahid Ahmed.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract